FOXP3 and neoplasm: Antigen-experienced CD4+ T cells can develop into Tregs by expressing CD25 or Foxp3 surface markers (47)—for example, using anti-CD25 monoclonal antibodies to enhance the anti-tumor immunity of mice (51, 52).